Cadrenal Therapeutics

CVKD · NASDAQ

$1.04−$0.02 (−1.89%)TodayMarket closed · Oct 20, 7:50 PM ET

Prev close $1.06

CVKD analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $14.28 (+1273.1% upside)

Low: $12.12
Now: $1.04
High: $17.85

Upgrades and downgrades

The latest rating actions, newest first

CVKD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Apr 7, 2026	Maintains	Buy	$32.00 → $13.00	40%

The case for and against

Updated Oct 31, 2025

Bull case

Cadrenal Therapeutics Inc. has entered a significant collaboration with Abbott to support the ongoing Phase 3 TECH-LVAD trial, which will assess the efficacy and safety of tecarfarin in patients requiring chronic anticoagulation. The recent transition of tecarfarin's drug substance manufacturing to a U.S.-based facility is expected to enhance Cadrenal's clinical and regulatory development strategy while also improving supply chain security. These developments point to a strong commitment to meeting unmet needs in anticoagulation therapy, positioning Cadrenal favorably within the market for novel anticoagulants.

Bear case

Cadrenal Therapeutics Inc.'s financial outlook is negatively impacted by several key factors, including the risk of failed or inconclusive clinical trials that could hinder the advancement of its drug candidate, tecarfarin. The company reported a first-quarter 2025 earnings per share (EPS) of ($2.09), which, while slightly better than estimated, underscores persistent financial challenges as it ended the quarter with only $7.3 million in cash reserves. This limited funding raises significant concerns about the company's ability to secure additional financing necessary for continued operations and drug development.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.